BioCentury
ARTICLE | Company News

Genta, National Institutes of Health deal

January 2, 2001 8:00 AM UTC

GNTA obtained an exclusive worldwide license to a decoy aptamer anti-cancer technology developed at NIH that uses short oligonucleotides to bind and act as competitive antagonists of cancer cell trans...